Shots:

• Yuhan to receive $40M as upfront & near-term payment and up to $830M milestones and royalties on sales. BI focuses to develop NASH treatment targeting key drivers of the disease i.e- steatosis- inflammation and fibrosis
•  The focus of the collaboration is to develop dual agonist combining GLP-1 and FGF21 activity in a single molecule for the treatment of NASH & other liver diseases and to expand BI’s NASH portfolio
• The dual agonist is a fusion protein utilizing the long-acting HyFc technology of Genexine- developed by Yuhan Corporation. Additionally- the collaboration of the companies is Korea’s first out-licensing of biologics targeting NASH

Click here to read full press release/ article | Ref: Boehringer Ingelheim | Image: MT Production